Skip Navigation

JNCI Journal of the National Cancer Institute 2003 95(19):1421; doi:10.1093/jnci/95.19.1421-b
© 2003 by Oxford University Press
This Article
Right arrow Full Text Freely available
Right arrow Japanese Translation
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Request Permissions
Google Scholar
Right arrow Search for Related Content

© 2003 Oxford University Press

IN THIS ISSUE

The first 10% of the full text of this article appears below.

Adjuvant Chemotherapy for Non–Small-Cell Lung Cancer

Although surgery is the primary treatment for patients with stage I, II, or IIIA non–small-cell lung cancer (NSCLC), the long-term survival of these patients is poor. Scagliotti et al. (p. 1453) conducted a randomized trial to examine the effects of mitomycin C, vindesine, and cisplatin every 3 weeks for three cycles (MVP group) or no treatment (control group) on patient survival after complete resection of NSCLC. The authors found no difference in overall or progression-free survival between the two patient groups. Among patients in the MVP . . . [Full Text of this Article]

Interval Carcinomas in a Prostate Screening Trial

Obesity, Tamoxifen Efficacy, and Breast Cancer Outcomes

Using COX-2 Inhibitors to Enhance Radiation Therapy

Selenium Supplementation and Nonmelanoma Skin Cancer

Germline BRCA1 Mutations and a Basal Epithelial Phenotype